Analysis of Prescription Drug Utilization with Beta Regression Models

<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
  <record>
    <leader>00000cab a2200000   4500</leader>
    <controlfield tag="001">MAP20220017589</controlfield>
    <controlfield tag="003">MAP</controlfield>
    <controlfield tag="005">20220613141619.0</controlfield>
    <controlfield tag="008">220613e20220613esp|||p      |0|||b|spa d</controlfield>
    <datafield tag="040" ind1=" " ind2=" ">
      <subfield code="a">MAP</subfield>
      <subfield code="b">spa</subfield>
      <subfield code="d">MAP</subfield>
    </datafield>
    <datafield tag="084" ind1=" " ind2=" ">
      <subfield code="a">6</subfield>
    </datafield>
    <datafield tag="100" ind1="1" ind2=" ">
      <subfield code="0">MAPA20140000234</subfield>
      <subfield code="a">Gan, Guojun</subfield>
    </datafield>
    <datafield tag="245" ind1="1" ind2="0">
      <subfield code="a">Analysis of Prescription Drug Utilization with Beta Regression Models</subfield>
      <subfield code="c">Guojun Gan, Emiliano A. Valdez</subfield>
    </datafield>
    <datafield tag="520" ind1=" " ind2=" ">
      <subfield code="a">The health care sector in the United States is complex and is also a large sector that generates about 20% of the country's gross domestic product. Health care analytics has been used by researchers and practitioners to better understand the industry. In this article, we examine and demonstrate the use of Beta regression models to study the utilization of brand name drugs in the United States to understand the variability of brand name drug utilization across different areas. The models are fitted to public datasets obtained from the Medicare & Medicaid Services and the Internal Revenue Service. Integrated nested Laplace approximation (INLA) is used to perform the inference. The numerical results show that Beta regression models can fit the brand name drug claim rates well and including spatial dependence improves the performance of the Beta regression models. Such models can be used to reflect the effect of prescription drug utilization when updating an insured's health risk in a risk scoring model.

</subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080540821</subfield>
      <subfield code="a">Drogas</subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080563288</subfield>
      <subfield code="a">Medicamentos</subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080606633</subfield>
      <subfield code="a">Industria farmacéutica</subfield>
    </datafield>
    <datafield tag="651" ind1=" " ind2="1">
      <subfield code="0">MAPA20080638337</subfield>
      <subfield code="a">Estados Unidos</subfield>
    </datafield>
    <datafield tag="700" ind1="1" ind2=" ">
      <subfield code="0">MAPA20080648428</subfield>
      <subfield code="a">Valdez, Emiliano A.</subfield>
    </datafield>
    <datafield tag="773" ind1="0" ind2=" ">
      <subfield code="w">MAP20077000239</subfield>
      <subfield code="g">13/06/2022 Tomo 26 Número 2 - 2022 , p. 205-226</subfield>
      <subfield code="x">1092-0277</subfield>
      <subfield code="t">North American actuarial journal</subfield>
      <subfield code="d">Schaumburg : Society of Actuaries, 1997-</subfield>
    </datafield>
  </record>
</collection>